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Background: The impact of liver transplantation (LTx) after surgical treatment for hepato-
cellular carcinoma (HCC) remains undefined. The aim of the current study was to assess
the impact of LTx and of selection criteria for LTx on the survival of patients who underwent
surgery for HCC.
Methods: Between 2004 and 2009, 119 patients underwent surgical treatment for HCC.
Cirrhosis was present in 85 patients. Of all patients, 77 fulfilled the Milan criteria, 88 the
UCSF and 87 the up-to-7 criteria. Finally, 35 patients received an LTx, of whom 31 met the
Milan, 33 the UCSF, and 33 the up-to-7 criteria. The relation between LTx and survival was
evaluated using a Cox regression model with LTx as a time-dependent factor.
Results: Median [95% confidence interval (CI)] disease-free survival (DFS) and overall sur-
vival (OS) of the entire patient population was 9.4 (7–12.2) and 49.1 (37.7–64) months,
respectively. The 1, 3, and 5-year DFS vs. OS rates were 36, 3, and 0% vs. 84.7, 61.7, and
39.6%, respectively. Patients fulfilling the Milan criteria had a significantly better OS and
DFS than those who had tumors beyond the Milan criteria (p<0.047). No significant dif-
ferences were observed in terms of OS between patients within vs. beyond the UCSF or
up-to-7 criteria (p>0.130). In multivariable analysis, cirrhotic patients who received an LTx
had a better OS, with a hazard ratio equal to 0.25 (95% CI: 0.08–0.74; p<0.01). LTx after
surgery had a beneficial impact on both DFS and OS of patients in all the three selection
criteria models of LTx (p<0.031).
Conclusion: LTx after primary surgery seems to offer the best long-term survival for
patients suffering from HCC in cirrhosis as well as for them who fulfill the Milan, UCSF,
and up-to-7 criteria.
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BACKGROUND
Hepatocellular carcinoma (HCC) is one of the most common
and aggressive malignancies worldwide (1). The vast majority of
patients with HCC have an underlying chronic liver disease, often
at the stage of cirrhosis. Factors responsible for the poor prognosis
include late onset diagnosis, underlying cirrhosis, and resistance
to chemotherapy. Despite current improvements in treatment and
diagnostics, only 30–40% of patients with HCC are eligible for
curative treatment options that include liver transplantation (LTx),
surgical resection, and local ablative therapies (LAT) (2–4).
To date, no randomized studies exist to compare results of these
therapeutic options and, therefore, no definite conclusion can be
drawn about which treatment offers the best outcome. In patients
with well-preserved liver function, surgical resection is currently
the standard of care for early-stage HCC (5, 6). Several minimally
invasive options can be offered to patients who are not eligible for
surgical resection. One of the most effective LAT is radiofrequency
ablation (RFA), which is now considered potentially curative for
selected patients with early-stage small HCC (7–9). On the other
hand, LTx is a suitable option for early HCC in cirrhotic patients,
though organ shortage remains a challenge hard to overcome.
The Milan criteria are most widely used to select candidates for
LTx, whereas the UCSF and up-to-7 criteria consider patients with
intermediate-stage tumors and those exceeding the Milan criteria
(10–12).
In the absence of well-designed randomized studies address-
ing the best therapeutic modality, the impact of bridging therapy
before LTx as well as that of LTx after surgical treatment for HCC
remains undefined. The aim of the current study was to assess the
impact of LTx and of selection criteria for LTx on the survival of
patients who underwent surgical treatment for HCC.
METHODS
PATIENT POPULATION
From January 2004 until April 2009, clinical data of 135 consec-
utive patients who underwent surgical treatment for HCC were
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collected prospectively. The study was approved by the KU Leu-
ven ethical committee prior to patient recruitment and received
the study number ML1295. The study was carried out in compli-
ance with the Helsinki declaration and written informed consent
was obtained from participants. Patients, who underwent their
primary liver surgery in another institution and were referred for
repeat hepatic surgery, were excluded from the study (n= 16).
Thus, 119 patients [male/female ratio 85/34; median (range) age
66 years (27–88 years) were considered for further analysis]. Liver
resection (LR) was performed in 53 patients, RFA in 58, and
LR+RFA in 8 patients.
Cirrhosis was present in 85 patients with a Child-Pugh
classification A in 65 patients, B in 19, and C in 1 patient.
The median (range) model for end-stage liver disease (MELD)
score was 9 (6–18). Pre-operative hepatic transarterial chemo-
embolization (TACE) with doxorubicin was performed in 14
patients within 3 months before liver surgery. The median serum
alpha-fetoprotein (AFP) level prior to surgery was 9.9µg/L (0.7–
113,300) while 18 patients had a level above 400µg/L. At the time
of surgery, benign ascites was observed in 14 patients. Liver fibro-
sis, confirmed on histopathology examination, was present in 11
patients.
Of the entire study population, 77 patients fulfilled the Milan
criteria, 88 the UCSF, and 87 the up-to-7 criteria. Finally, 35
patients received an LTx at a median time interval of 7.3 (1.7–
34.6) months after surgery. Of these patients, 31 met the Milan
criteria, 33 the UCSF, and 33 the up-to-7 criteria.
SURGICAL PROCEDURE
Laparoscopic liver surgery (LLS) (resection 13; RFA 54; resec-
tion+RFA 5) was performed in 72 patients for a total of 93 tumors
(13 patients with 2 and 4 patients with 3 tumors). The median
(range) of the maximum tumor diameter in the LLS-group was
26.5 mm (12–190). Open liver surgery (OLS) (resection 40; RFA 4;
resection+RFA 3) was performed in 47 patients for a total of 55
tumors (8 patients with 2 tumors). The median of the maximum
tumor diameter in the OLS-group was 70 mm (8–240). Tumor
diameter and the resection/RFA ratio were higher in the OLS-
vs. LLS-group (p< 0.001). RFA was considered for patients with
HCC smaller than 3 cm in diameter, for unresectable HCC, and
lesions in contact with major vascular structures to obtain tumor-
free resection margins or result in too small liver remnant. Major
liver resection (>3 segments) was performed in 26 and minor (<2
segments) resection in 35 patients.
FOLLOW-UP
Patient follow-up was closed in September 2010, with a
median follow-up time after surgery of 29.8 (range 0–75.1)
months (including deceased patients). Follow-up information was
obtained through review of patients’ hospital charts that were
prospectively registered in our institution’s database. Postoperative
follow-up investigations consisted of a clinical examination, bio-
chemistry including serum AFP level, magnetic resonance imag-
ing (MRI) scan of the liver, and a contrast-enhanced computed
tomography (CT) scan of thorax performed every 3–4 months.
Recurrent disease was defined as a radiological mass characterized
as a malignant lesion on MRI- and/or CT-scan.
OUTCOME MEASURES AND PREDICTIVE FACTORS
Postoperative complications were classified based on the therapy-
oriented severity grading system (TOSGS) and allocated to surgical
site (SSC) vs. non-surgical site complications (NSSC) (13). Overall
survival (OS) was defined as time from surgery to death, irre-
spective of cause. Disease-free survival (DFS) was defined as time
to tumor recurrence or death, irrespective of cause. Cox regres-
sion analyses were performed to assess the prognostic value of
18 potential predictive factors, i.e., age, gender, American Soci-
ety of Anesthesiologists (ASA) score, serum AFP level, number
of tumors, maximum tumor diameter, Child-Pugh score, MELD
score, location of HCC (right/left liver), resection, RFA, extent of
liver resection (major or minor), pre-operative TACE, presence
of intra-operative ascites, cirrhosis, liver fibrosis, and LTx after
surgery.
STATISTICAL ANALYSIS
Mann–Whitney U and Fisher Exact tests were used to compare
patient variables between two groups. Cumulative incidence esti-
mates were used to construct a curve for time to liver transplant
(TLTx), considering death without an LTx as a competing event.
Pepe and Mori’s test was used to compare this curve between MILS
and OLS. Log-rank tests and Cox regression models were used to
verify the relation between the set of predictors and TLTx, OS,
and DFS, respectively. For OS and DFS, patients lost to follow-up
were censored. In the analysis of TLTx, deaths without LTx were
also censored. The proportional hazards assumption and the func-
tional form of the continuous predictors were verified by applying
graphical and numerical methods.
Kaplan–Meier estimates were used to construct curves for OS
and DFS, which were compared between groups using a log-rank
test. Since the moment of LTx differed between patients, the rela-
tion between LTx and survival was evaluated using a Cox regression
model with LTx as a (irreversible) time-dependent factor. Treat-
ing LTx as a time-varying factor implies that at the moment of
surgery all patients belong to the no-transplant group; when a
patient receives an LTx he/she switches to the transplant group.
P-values that are smaller than 0.05 were considered signifi-
cant. Analyses were performed using SAS software, version 9.2 of
the SAS System for Windows (Copyright©2002 SAS Institute Inc.,
SAS and all other SAS Institute Inc., product or service names are
registered trademarks or trademarks of SAS Institute Inc., Cary,
NC, USA).
RESULTS
POSTOPERATIVE OUTCOME
Postoperative complications were observed in 22 (18.5%) patients.
According to the TOSGS score, the severity of postoperative com-
plications were grade 1 in 2, grade 2 in 6, grade 3b in 5, grade 4a in
4, grade 4b in 1, and grade 5 or death in 4 patients. Complications
were allocated to SSC in 8 and NSSC in 14 patients. The median
postoperative length of hospital stay (LOS) was 6 days (range 1–27;
IQR 3–10).
LONG-TERM SURVIVAL
The median [95% confidence interval (CI)] DFS and OS of the
entire patient population was 9.4 (7–12.2) and 49.1 (37.7–64)
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Table 1 | Survival after surgery for HCC in patients as classified according to criteria for liver transplant.
Criteria for
liver transplant
Disease-free survival Overall survival
Median (95% CI);
months
1 years
(%)
3 years
(%)
5 years
(%)
Log-rank
p-value
Median (range);
months
1 years
(%)
3 years
(%)
5 years
(%)
Log-rank
p-value
Milan Yes (n 77) 35.2 (25.3-ND) 67.4 45.5 42.8 0.016 53.0 (39.4-ND) 88.1 64.7 47.1 0.047
No (n 42) 14.6 (7.8–21.2) 53.9 28.6 19.1 39.4 (24.0–58.8) 76.1 52.5 26.2
UCSF Yes (n 88) 31.7 (20.6-ND) 69.9 44.0 41.5 0.006 49.1 (39.4–68.4) 86.1 64.8 42.7 0.237
No (n 31) 10.8 (5.6–26.4) 45.8 26.6 13.3 39.4 (14.9-ND) 77.3 52.0 28.9
Up-to-7 Yes (n 87) 31.7 (19.7-ND) 69.9 44.0 41.5 0.007 53.0 (39.4–68.4) 88.3 65.6 43.2 0.130
No (n 32) 12.2 (5.6–26.4) 46.3 27.0 13.5 39.4 (12.4-ND) 71.6 50.9 28.3
FIGURE 1 | Overall survival of cirrhotic patients with HCC after surgery
and liver transplantation vs. surgery alone. Survival curves are obtained
from a Cox regression with liver transplant as a time-dependent variable.
The solid line represents patients without a liver transplant. The non-solid
lines represent hypothetical samples of patients who receive a liver
transplant after 3 and 12 months, respectively.
months, respectively. The 1, 3, and 5-year DFS vs. OS rates were
36, 3, and 0% vs. 84.7, 61.7, and 39.6%, respectively.
Patients fulfilling the Milan criteria had a significantly better
OS and DFS than those who had tumors beyond the Milan cri-
teria (p< 0.047) (Table 1). Disease-free survival rates were better
in patients within both the UCSF (p= 0.006) and the up-to-7
(p= 0.007) criteria as compared to that of patients beyond these
criteria. No significant differences were observed in terms of OS
between patients within vs. beyond the UCSF or up-to-7 criteria
(p> 0.130) (Table 1).
Median OS of patients who met the Milan criteria and who
underwent LTx after surgery was 64 months (CI 45.5 – undeter-
mined) as compared to 35.2 months (CI 24.2 – undetermined)
in patients who were treated with surgery alone (p= 0.035)
(Figure 1). The hazard ratio (HR) comparing the OS of cirrhotic
patients who underwent LTx with patients who did not undergo
LTx was equal to 0.38 (95% CI: 0.17–0.87; p= 0.022). In all bivari-
able models, LTx remained a significant favorable factor for OS (all
p-values <0.05), with the HR in the same range as in the univari-
able setting. Also in the multivariable model, cirrhotic patients
Table 2 | Survival after surgery for HCC as function of liver transplant
in patients classified within liver transplant criteria.
Survival N
total
N
LTx
N
event
HR 95% CI p-Value
Milan OS 63 27 26 0.367 0.148–0.914 0.031
DFS 63 27 43 0.141 0.047–0.421 <0.001
UCSF OS 68 29 29 0.359 0.151–0.853 0.020
DFS 68 29 47 0.155 0.057–0.418 <0.001
Up-to-7 OS 68 29 29 0.351 0.148–0.830 0.017
DFS 68 29 47 0.154 0.057–0.416 <0.001
LL, UL, lower and upper limit of 95% confidence interval (CI); N event, number
of events; N OLT, number of subjects with LTx; N tot, total number of patients;
OS, overall survival.
Results from a Cox regression with liver transplant (LTx) as a (irreversible) time-
dependent factor DFS, disease-free survival; HR, hazard ratio transplant yes vs.
no.
who received an LTx had a better OS, with a HR equal to 0.25
(95% CI: 0.08–0.74; p< 0.01). In multivariable analysis, LTx after
surgery had a beneficial impact on both DFS and OS of patients
in all the three selection criteria models of LTx (Table 2).
DISCUSSION
The management of patients with HCC continues to evolve as
modern anticancer therapies and improved surgical treatment
strategies have translated into better oncologic outcomes. Though,
in the absence of high-level evidence to compare results of vari-
ous surgical therapeutic options, it is not clear which treatment
offers the best outcome. Today, LTx seems to be the treatment of
choice for early HCC in cirrhotic patients, whereas organ shortage
and advances in minimally invasive treatment modalities are chal-
lenging the timing and the role of LTx. Although currently OLS is
the preferable approach, increasingly more data from specialized
centers become available on the safety, feasibility, and even some
on the efficacy of minimally invasive liver surgery to treat selected
patients with early-stage HCC.
In the current study,we present the results of all consecutive sur-
gically treated patients with HCC from one single institution over
a time period of 5 years. A set of 18 variables was taken into consid-
eration to analyze prognostic factors in a cohort of patients with
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various stages of HCC. We found postoperative LTx as the only
independent predictor of both OS and DFS in cirrhotic patients
with HCC. Retrospective studies suggest that survival rates for
HCC without cirrhosis after LTx are as good as after LR. Though,
patients with cirrhosis as an underlying cause of HCC seem to
have better outcomes after LTx compared to LR (14–18). However,
only a small proportion of patients with cirrhosis is identified in
the early-stage of HCC, and thus are candidates within the Milan
criteria for LTx. Moreover, lack of donor organ is another major
reason of ineligibility. Consequently, LR remains an important
therapeutic option in cirrhotic and non-cirrhotic patients with
HCC and well-preserved liver function.
The role of LR as bridging therapy for secondary LTx has also
been evaluated. The fundamental idea for bridging therapy is to
intercept tumor progression and thus, dropout of the transplan-
tation list by LR as waiting times for LTx are long because of
organ shortage and LR can be performed without delay. Sev-
eral studies suggested the feasibility of this strategy and found
no difference in morbidity or long-term survival between primary
and secondary (after initial LR) LTx (19–21). Laparoscopically
performed bridging LR may hereby facilitate the secondary LTx
in terms of reduced operative time, blood loss, and transfusion
needs (22). In contrast, some studies investigating the outcomes
of secondary LTx in the case of underlying cirrhosis suggested the
negative impact of this strategy on transplant ability, DFS, and
OS (23, 24). In the present study, patients who underwent surgi-
cal treatment for HCC within the Milan criteria and subsequently
received an LTx had a better survival compared to patients who
where treated with surgery alone. LTx offers not only a treatment
for the tumor but simultaneously cures the underlying disease,
preventing late recurrence. Indeed, in cirrhotic patients with HCC,
we found postoperative LTx as the only independent predictor of
survival. Another advantage of LR is that it can serve as a selection
tool for LTx. Patients with an unfavorable tumor profile and thus
high recurrence risk, are preferably treated by other modalities
than LTx. Indeed, analysis of strong pathologic predictive factors
for recurrence like microvascular invasion or poor histological dif-
ferentiation can only be performed on the tumor specimen (25).
Regarding the three selection criteria systems of LTx candidates
(Milan, UCSF, up-to-7) in the entire patient population, we found
DFS to be better in patients who met these criteria than in patients
who did not. OS, however, was best in patients who only met the
Milan criteria. On the other hand, the impact of LTx after surgery
was beneficial on both DFS and OS of patients in all the three
selection criteria models of LTx.
CONCLUSION
Liver transplantation after primary surgery seems to offer the best
long-term survival for patients suffering from HCC in cirrho-
sis as well as for them who fulfill the Milan, UCSF, and up-to-7
criteria. However, shortage of organ donors and relatively high
dropout rates on the waiting list are major concerns. Novel treat-
ment strategies are urgently needed in order to improve survival
of the increasing number of patients, either as a bridging therapy
to LTx while waiting on the list for a transplant, or as alternative
therapeutic modalities for those who are no candidates for LTx.
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